Bayer develops the follow-up NOAC of Xarelto, strengthening its pipeline
Bayer has put much effort on the development of another new oral anticoagulant(NOAC).
According to the industry concerned on the 17th, the new oral anticoagulant is a factor XI inhibitor unlike ‘Xarelto(rivaroxaban)’ inhibiting the coagulation factor X. Bayer is currently preparing for a Phase 2...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
